For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
13
views
22
references
 Top references
cited by
4
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      578
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Povidone-iodine for the management of oral mucositis during cancer therapy

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Oral mucositis (OM) is a common and often dose-limiting side effect of cancer therapy. Povidone iodine (PVP-I) formulations have been shown to decrease the incidence and severity of OM, but the relevance of these findings remains unclear. The objective of the present study was to review evidence for the use of PVP-I for OM management. An algorithm identified relevant articles published online, and a panel of experts with experience in the management of OM reviewed the findings. Six studies fulfilled the criteria for full review. Two studies provided evidence of moderate quality. Two of the studies with negative findings were confounded by the use of PVP-I concentrations that are too low to be efficacious. The remaining two studies were found to have design flaws. There exists reasonable evidence to support a recommendation for the use of PVP-I in the management of cancer therapy-related OM.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Updated clinical practice guidelines for the prevention and treatment of mucositis.

          Mark Schubert, , Linda S. Elting … (2007)
          Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastrointestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients. Cancer 2007;109:820-31. (c) 2007 American Cancer Society.
          Article 0 comments Cited 132 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Practical use of povidone‐iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections

            J Kanagalingam, R. Feliciano, J. Hah … (2015)
            Summary Aims To better inform medical practitioners on the role of antiseptics in oropharyngeal health and disease, this article focuses on povidone‐iodine (PVP‐I), an established and widely‐available antiseptic agent. Methodology Review of the anti‐infective profile, efficacy and safety of PVP‐I in managing common upper respiratory tract infections such as the common cold, influenza and tonsillo‐pharyngitis, as well as oral complications resulting from cancer treatment (oral mucositis), and dental conditions (periodontitis, caries). Results Antiseptics with broad‐spectrum anti‐infective activity and low resistance potential offer an attractive option in both infection control and prevention. While there is some evidence of benefit of antiseptics in a variety of clinical settings that include dental and oral hygiene, dermatology, oncology, and pulmonology, there appears to be discordance between the evidence‐base and practice. This is especially apparent in the management and prevention of oropharyngeal infections, for which the use of antiseptics varies considerably between clinical practices, and is in marked contrast to their dermal application, where they are extensively used as both a prophylaxis and a treatment of skin and wound infections, thus minimising the use of antibiotics. Conclusion The link between oral and oropharyngeal health status and susceptibility to infection has long been recognised. The high rates of antibiotic misuse and subsequent development of bacterial resistance (e.g. increasing vancomycin‐resistant enterococci (VRE) and methicillin‐resistant Staphylococcus aureus (MRSA)) in large parts of the world, especially across Asia Pacific, highlight the need for identifying alternative antimicrobials that would minimise the use of these medications. This, together with recent large‐scale outbreaks of, for example, avian and swine influenza virus, further underline the importance of an increasing armamentarium for infection prevention and control.
            Article 0 comments Cited 36 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro.

              C.J. Beukelman, A.J.J. van den Berg, M.J. Hoekstra … (2008)
              A liposomal hydrogel with 3% povidone-iodine (PVP-ILH, Repithel) has shown clinical benefit in settings where inflammation and/or reactive oxygen species are thought to impede wound healing (e.g., burns, chronic wounds and in smokers). This in vitro study investigated whether PVP-ILH is able to reduce inflammatory events responsible for the impairment of the wound healing process in such patients. Therefore, the following assays were conducted with PVP-ILH (and derived control hydrogels to identify the component responsible for the effect): inhibition of reactive oxygen species production by human polymorphonuclear neutrophils (PMNs) and in a cell-free system, oxygen consumption assay of PMNs (prior to oxidative burst), inhibition of human complement (limiting the generation of complement factors), mast cell degranulation, nitric oxide production by murine macrophages and TNF-alpha production by human monocytes/macrophages. Where toxicity could cause cell inhibition, cell viability was assessed. PVP-ILH and its components interacted in our series of bioassays at various stages in the inflammation cascade. Scavenging of superoxide anions was the most pronounced effect. Furthermore, povidone-iodine inhibited PMN production of reactive oxygen species (inhibition of oxygen consumption) and a mast cell inhibitory (stabilising) activity was observed. Based on these results, the clinically observed, beneficial wound healing effects of PVP-ILH may also be attributed to an impediment of inflammatory activity, mainly by iodine's free radical scavenging. Controlling oxidative stress in the wound may be of great importance, especially since further reactions as, e.g., the formation of peroxynitrite from NO and ROS are prevented.
              Article 0 comments Cited 30 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Oncol Rev
                Journal ID (iso-abbrev): Oncol Rev
                Journal ID (publisher-id): ONCOL
                Title: Oncology Reviews
                Publisher: PAGEPress Publications, Pavia, Italy
                ISSN (Print): 1970-5565
                ISSN (Electronic): 1970-5557
                Publication date (Electronic): 15 September 2017
                Publication date Collection: 14 June 2017
                Volume: 11
                Issue: 2
                Electronic Location Identifier: 341
                Affiliations
                [1 ]Lee Kong Chian School of Medicine, Johns Hopkins Singapore IMC and Tan Tock Seng Hospital, The ENT Clinic, Mount Elizabeth Novena Hospital, Singapore
                [2 ]OncoCare, Mount Elizabeth Medical Centre , Mount Elizabeth, Singapore
                [3 ]Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System , Seoul, Korea
                [4 ]Ibn Nafees Medical Center, Abu Dhabi, United Arab Emirates
                [5 ]Manila Doctors Hospital, Manila, Philippines
                [6 ]Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan
                Author notes
                Jin-Ching Lin, Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung, Taiwan. jclin@ 123456vghtc.gov.tw
                Article
                DOI: 10.4081/oncol.2017.341
                PMC ID: 5607850
                PubMed ID: 28959380
                SO-VID: a82b606f-0905-4066-865a-d3d1fe592229
                Copyright © ©Copyright F. Diomede et al, 2017
                License:

                This article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

                History
                Date received : 26 April 2017
                Date accepted : 21 August 2017
                Page count
                Figures: 1, Tables: 2, Equations: 0, References: 30, Pages: 6
                Categories
                Subject: Review

                Keywords: povidone iodine,chemotherapy,radiotherapy,cancer,mucositis
                Data availability:
                Keywords: povidone iodine, chemotherapy, radiotherapy, cancer, mucositis

                Comments

                Comment on this article

                scite_

                Similar content578

                See all similar

                Cited by4

                See all cited by

                Most referenced authors235

                See all reference authors